The efficacy and safety of inhaled human α-1 antitrypsin in people with α-1 antitrypsin deficiency-related emphysema

References

• Greene CM, McElvaney NG. Proteases and antiproteases in chronic neutrophilic lung disease – relevance to drug discovery. Br J Pharmacol 2009;158(4):1048-58
   PubMed Web of Science ®Google Scholar
• Greene CM, Miller SD, Carroll T, et al. Alpha-1 antitrypsin deficiency: a conformational disease associated with lung and liver manifestations. J Inherit Metab Dis 2008;31(1):21-34
   Google Scholar
• Kelly E, Greene CM, Carroll TP, et al. Alpha-1 antitrypsin deficiency. Respir Med 2010;104(6):763-72
   PubMed Web of Science ®Google Scholar
• Petrache I, Fijalkowska I, Medler TR, et al. alpha-1 antitrypsin inhibits caspase-3 activity, preventing lung endothelial cell apoptosis. Am J Pathol 2006;169(4):1155-66
   PubMed Web of Science ®Google Scholar
• Petrache I, Fijalkowska I, Zhen L, et al. A novel antiapoptotic role for alpha1-antitrypsin in the prevention of pulmonary emphysema. Am J Respir Crit Care Med 2006;173(11):1222-8
   PubMed Web of Science ®Google Scholar
• Bergin DA, Reeves EP, Meleady P, et al. alpha-1 Antitrypsin regulates human neutrophil chemotaxis induced by soluble immune complexes and IL-8. J Clin Invest 2010;120(12):4236-50
   PubMed Web of Science ®Google Scholar
• Bellacen K, Kalay N, Ozeri E, et al. Revascularization of pancreatic islet allografts is enhanced by alpha-1-antitrypsin under anti-inflammatory conditions. Cell Transplant 2012;22(11):2119-33
   Google Scholar
• Survival and FEV1 decline in individuals with severe deficiency ofalpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med 1998;158(1):49-59
   PubMed Web of Science ®Google Scholar
• Seersholm N, Wencker M, Banik N, et al. Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group. Eur Respir J 1997;10(10):2260-3
   PubMed Web of Science ®Google Scholar
• Chapman KR, Burdon JG, Piitulainen E, et al. IV Alpha1 Antitrypsin (A1AT) Preserves Lung Density In Homozygous Alpha1 Antitrypsin Deficiency (A1ATD); A Randomized, Placebo-Controlled Trial American journal of respiratory and critical care medicine. C20. Late Breaking Abstracts in Clinical Trials A6069 2013
   Google Scholar
• Dirksen A, Piitulainen E, Parr DG, et al. Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiency. Eur Respir J 2009;33(6):1345-53
   PubMed Web of Science ®Google Scholar
• Dirksen A, Dijkman JH, Madsen F, et al. A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. Am J Respir Crit Care Med 1999;160(5 Pt 1):1468-72
   PubMed Web of Science ®Google Scholar
• Mullins CD, Huang X, Merchant S, Stoller JK. The direct medical costs of alpha(1)-antitrypsin deficiency. Chest 2001;119(3):745-52
   PubMed Web of Science ®Google Scholar
• Silverman EK, Sandhaus RA. Clinical practice. Alpha1-antitrypsin deficiency. N Engl J Med 2009;360(26):2749-57
   PubMed Web of Science ®Google Scholar
• McCarthy C, Dimitrov BD. Augmentation therapy for alpha-1 antitrypsin deficiency--not enough evidence to support its use yet!. Copd 2010;7(3):234-235-6
   Google Scholar
• Bergin DA, Reeves EP, Hurley K, et al. The circulating proteinase inhibitor α-1 antitrypsin regulates neutrophil degranulation and autoimmunity. Sci Transl Med 2014;6(217):217ra1
   Web of Science ®Google Scholar
• Sandhaus RA, Turino G. Neutrophil elastase-mediated lung disease. COPD 2013;10(Suppl 1):60-3
   PubMedGoogle Scholar
• Lomas DA, Parfrey H. Alpha1-antitrypsin deficiency. 4: molecular pathophysiology. Thorax 2004;59(6):529-35; Review
   PubMed Web of Science ®Google Scholar
• Ogushi F, Fells GA, Hubbard RC, et al. Z-type alpha 1-antitrypsin is less competent than M1-type alpha 1-antitrypsin as an inhibitor of neutrophil elastase. J Clin Invest 1987;80(5):1366-74
   Google Scholar
• Molloy K, Hersh CP, Morris VB, et al. Clarification of the risk of chronic obstructive pulmonary disease in α1-antitrypsin deficiency PiMZ heterozygotes. Am J Respir Crit Care Med 2014;189(4):419-27
   PubMed Web of Science ®Google Scholar
• Crystal RG. Alpha 1-antitrypsin deficiency, emphysema, and liver disease. Genetic basis and strategies for therapy. J Clin Invest 1990;85(5):1343-52; Review
   Web of Science ®Google Scholar
• Hubbard RC, McElvaney NG, Sellers SE, et al. Recombinant DNA-produced alpha 1-antitrypsin administered by aerosol augments lower respiratory tract antineutrophil elastase defenses in individuals with alpha 1-antitrypsin deficiency. J Clin Invest 1989;84(4):1349-54
   PubMed Web of Science ®Google Scholar
• Hubbard RC, Brantly ML, Sellers SE, et al. Anti-neutrophil-elastase defenses of the lower respiratory tract in alpha 1-antitrypsin deficiency directly augmented with an aerosol of alpha 1-antitrypsin. Ann Intern Med 1989;111(3):206-12
   PubMed Web of Science ®Google Scholar
• Rennard SI, Basset G, Lecossier D, et al. Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J Appl Physiol 1985;60(2):532-8
   Google Scholar
• Vogelmeier C, Buhl R, Hoyt RF, et al. Aerosolization of recombinant SLPI to augment antineutrophil elastase protection of pulmonary epithelium. J Appl Physiol 1990;69(5):1843-8
   Google Scholar
• Smith RM, Traber LD, Traber DL, Spragg RG. Pulmonary deposition and clearance of aerosolized alpha-1-proteinase inhibitor administered to dogs and to sheep. J Clin Invest 1989;84(4):1145-54
   PubMed Web of Science ®Google Scholar
• McElvaney NG, Hubbard RC, Birrer P, et al. Aerosol alpha 1-antitrypsin treatment for cystic fibrosis. Lancet 1991;337(8738):392-4
   PubMed Web of Science ®Google Scholar
• Griese M, Latzin P, Kappler M, et al. alpha1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients. Eur Respir J 2007;29(2):240-50
   PubMed Web of Science ®Google Scholar
• Berger M, Sorensen RU, Tosi MF, et al. Complement receptor expression on neutrophils at an inflammatory site, the Pseudomonas-infected lung in cystic fibrosis. J Clin Invest 1989;84(4):1302-13
   PubMed Web of Science ®Google Scholar
• Hartl D, Latzin P, Hordijk P, et al. Cleavage of CXCR1 on neutrophils disables bacterial killing in cystic fibrosis lung disease. Nat Med 2007;13(12):1423-30
   PubMed Web of Science ®Google Scholar
• Hill AT, Bayley DL, Campbell EJ, et al. Airways inflammation in chronic bronchitis: the effects of smoking and alpha1-antitrypsin deficiency. Eur Respir J 2000;15(5):886-90
   Google Scholar
• Hubbard RC, Fells G, Gadek J, et al. Neutrophil accumulation in the lung in alpha 1-antitrypsin deficiency. Spontaneous release of leukotriene B4 by alveolar macrophages. J Clin Invest 1991;88(3):891-7
   PubMed Web of Science ®Google Scholar
• Stockley RA, Bayley DL, Unsal I, Dowson LJ. The effect of augmentation therapy on bronchial inflammation in alpha1-antitrypsin deficiency. Am J Respir Crit Care Med 2002;165(11):1494-8
   PubMed Web of Science ®Google Scholar
• Geraghty P, Rogan MP, Greene CM, et al. Neutrophil elastase up-regulates cathepsin B and matrix metalloprotease-2 expression. J Immunol 2007;178(9):5871-8
   PubMed Web of Science ®Google Scholar
• Taggart CC, Lowe GJ, Greene CM, et al. Cathepsin B, L, and S cleave and inactivate secretory leucoprotease inhibitor. J Biol Chem 2001;276(36):33345-52
   PubMed Web of Science ®Google Scholar
• Rogan MP, Taggart CC, Greene CM, et al. Loss of microbicidal activity and increased formation of biofilm due to decreased lactoferrin activity in patients with cystic fibrosis. J Infect Dis 2004;190(7):1245-53
   PubMed Web of Science ®Google Scholar
• Taggart CC, Greene CM, Smith SG, et al. Inactivation of human beta-defensins 2 and 3 by elastolytic cathepsins. J Immunol 2003;171(2):931-7
   PubMed Web of Science ®Google Scholar
• Bergsson G, Reeves EP, McNally P, et al. LL-37 complexation with glycosaminoglycans in cystic fibrosis lungs inhibits antimicrobial activity, which can be restored by hypertonic saline. J Immunol 2009;183(1):543-51
   Google Scholar
• Geraghty P, Rogan MP, Greene CM, et al. Alpha-1-antitrypsin aerosolised augmentation abrogates neutrophil elastase-induced expression of cathepsin B and matrix metalloprotease 2 in vivo and in vitro. Thorax 2008;63(7):621-6
   Google Scholar
• Ma S, Lin YY, He J, et al. Alpha-1 antitrypsin augmentation therapy and biomarkers of elastin degradation. COPD 2013;10(4):473-81
   PubMedGoogle Scholar
• Brand P, Schulte M, Wencker M, et al. Lung deposition of inhaled alpha1-proteinase inhibitor in cystic fibrosis and alpha1-antitrypsin deficiency. Eur Respir J 2009;34(2):354-60
   PubMed Web of Science ®Google Scholar
• Vogelmeier C, Kirlath I, Warrington S, et al. The intrapulmonary half-life and safety of aerosolized alpha1-protease inhibitor in normal volunteers. Am J Respir Crit Care Med 1997;155(2):536-41
   PubMed Web of Science ®Google Scholar
• Kropp J, Wencker M, Hotze A, et al. Inhalation of [123I]alpha1-protease inhibitor: toward a new therapeutic concept of alpha1-protease inhibitor deficiency? J Nucl Med 2001;42(5):744-51
   PubMed Web of Science ®Google Scholar
• Martin SL, Downey D, Bilton D, et al. Safety and efficacy of recombinant alpha(1)-antitrypsin therapy in cystic fibrosis. Pediatr Pulmonol 2006;41(2):177-83
   PubMed Web of Science ®Google Scholar
• Spencer LT, Humphries JE, Brantly ML; Transgenic Human Alpha 1-Antitrypsin Study Group. Antibody response to aerosolized transgenic human alpha1-antitrypsin. N Engl J Med 2005;352(19):2030-1
   PubMed Web of Science ®Google Scholar
• Hubbard RC, Crystal RG. Strategies for aerosol therapy of alpha 1-antitrypsin deficiency by the aerosol route. Lung 1990;168(Suppl):565-78
   PubMed Web of Science ®Google Scholar
• International Study Evaluating the Safety and Efficacy of Inhaled, Human, Alpha-1 Antitrypsin (AAT) in Alpha-1 Antitrypsin Deficient Patients With Emphysema. Available from: https://clinicaltrials.gov/ct2/show/NCT01217671
   Google Scholar
• Phase II, Safety and ELF Study of “Kamada-API for Inhalation”. Available from: https://clinicaltrials.gov/ct2/show/NCT02001688
   Google Scholar
• King MB, Campbell EJ, Gray BH, Hertz MI. The proteinase-antiproteinase balance in alpha-1-proteinase inhibitor-deficient lung transplant recipients. American journal of respiratory and critical care medicine 1994;149(4 Pt 1):966-71
   PubMed Web of Science ®Google Scholar
• Banga A, Gildea T, Rajeswaran J, et al. The natural history of lung function following lung transplantation for alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 2014;190(3):274-81. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar